{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:09:58Z","timestamp":1787688598480,"version":"build-2784847793"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005601","name":"CLL Global Research Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain. BTK is a pivotal protein for B cell receptor signaling and tissue homing of CLL cells. Preclinical investigations have established the importance of the B cell receptor pathway in the maintenance and survival of normal and malignant B cells, underscoring the importance of targeting this axis for CLL. Clinical trials demonstrated overall and progression-free survival benefit with ibrutinib in multiple CLL subgroups, including patients with relapsed or refractory disease, patients with 17p deletion, elderly patients, and treatment-na\u00efve patients. Consequently, ibrutinib was approved by the US Food and Drug Administration for newly diagnosed and relapsed disease. Ibrutinib has transformed the treatment of CLL; however, several limitations have been identified, including low complete remission rates, development of resistance, and uncommon substantial toxicities. Further, ibrutinib must be used until disease progression, which imposes a financial burden on patients and society. These limitations were the impetus for the development of ibrutinib combinations. Four strategies have been tested in recent years: combinations of ibrutinib with immunotherapy, chemoimmunotherapy, cell therapy, and other targeted therapy. Here, we review the scientific rationale for and clinical outcome of each strategy. Among these strategies, ibrutinib with targeted agent venetoclax results in high complete response rates and, importantly, high rates of undetectable minimal residual disease. Although we concentrate here on ibrutinib, similar combinations are expected or ongoing with acalabrutinib, tirabrutinib, and zanubrutinib, second-generation BTK inhibitors. Future investigations will focus on the feasibility of discontinuing ibrutinib combinations after a defined time; the therapeutic benefit of adding a third agent to ibrutinib-containing combinations; and profiling of resistant clones that develop after combination treatment. A new standard of care for CLL is expected to emerge from these investigations.<\/jats:p>","DOI":"10.1038\/s41408-021-00467-7","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T10:05:37Z","timestamp":1619690737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Ibrutinib combinations in CLL therapy: scientific rationale and clinical results"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6985-3509","authenticated-orcid":false,"given":"Natalia","family":"Timofeeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-9166","authenticated-orcid":false,"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075\u201313080 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"467_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu, J., Zhang, M. & Liu, D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J. Hematol. Oncol. 9, 21 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"467_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter, H. S. et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127, 411\u2013419 (2016).","journal-title":"Blood"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","volume":"126","author":"C Tam","year":"2015","unstructured":"Tam, C. et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/ refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood 126, 832\u2013832 (2015).","journal-title":"Blood"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu, J., Liu, C., Tsui, S. T. & Liu, D. Second-generation inhibitors of Bruton tyrosine kinase. J. Hematol. Oncol. 9, 80 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J. Clin. Oncol. 31, 88\u201394 (2013).","journal-title":"J. Clin. Oncol."},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32\u201342 (2013).","journal-title":"N. Engl. J. Med."},{"key":"467_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","volume":"15","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien, S. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol. 15, 48\u201358 (2014).","journal-title":"Lancet Oncol."},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd, J. C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213\u2013223 (2014).","journal-title":"N. Engl. J. Med."},{"key":"467_CR10","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger, J. A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373, 2425\u20132437 (2015).","journal-title":"N. Engl. J. Med."},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O\u2019Brien","year":"2016","unstructured":"O\u2019Brien, S. et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 17, 1409\u20131418 (2016).","journal-title":"Lancet Oncol."},{"key":"467_CR12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","volume":"133","author":"JC Byrd","year":"2019","unstructured":"Byrd, J. C. et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 133, 2031\u20132042 (2019).","journal-title":"Blood"},{"key":"467_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien, S. et al. Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131, 1910\u20131919 (2018).","journal-title":"Blood"},{"key":"467_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1182\/blood.2019003570","volume":"135","author":"P Strati","year":"2020","unstructured":"Strati, P. et al. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood 135, 510\u2013513 (2020).","journal-title":"Blood"},{"key":"467_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato, A. R. et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica 103, 874\u2013879 (2018).","journal-title":"Haematologica"},{"key":"467_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589","volume":"7","author":"JA Burger","year":"2016","unstructured":"Burger, J. A. et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat. Commun. 7, 11589 (2016).","journal-title":"Nat. Commun."},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Ibrutinib resistance in chronic lymphocytic leukemia. N. Engl. J. Med. 370, 2352\u20132354 (2014).","journal-title":"N. Engl. J. Med."},{"key":"467_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","volume":"126","author":"TM Liu","year":"2015","unstructured":"Liu, T. M. et al. Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood 126, 61\u201368 (2015).","journal-title":"Blood"},{"key":"467_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach, J. A. et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J. Clin. Oncol. 35, 1437\u20131443 (2017).","journal-title":"J. Clin. Oncol."},{"key":"467_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/sji.12333","volume":"82","author":"A Berglof","year":"2015","unstructured":"Berglof, A. et al. Targets for ibrutinib beyond B cell malignancies. Scand. J. Immunol. 82, 208\u2013217 (2015).","journal-title":"Scand. J. Immunol."},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd, J. C. et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125, 2497\u20132506 (2015).","journal-title":"Blood"},{"key":"467_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2017.175","volume":"32","author":"JR Brown","year":"2018","unstructured":"Brown, J. R. et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL. Leukemia 32, 83\u201391 (2018).","journal-title":"Leukemia"},{"key":"467_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-018-0461-y","volume":"13","author":"T Hilal","year":"2018","unstructured":"Hilal, T., Betcher, J. A. & Leis, J. F. Economic impact of oral therapies for chronic lymphocytic leukemia-the burden of novelty. Curr. Hematol. Malig. Rep. 13, 237\u2013243 (2018).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"467_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"SS Chen","year":"2016","unstructured":"Chen, S. S. et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30, 833\u2013843 (2016).","journal-title":"Leukemia"},{"key":"467_CR25","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123, 1810\u20131817 (2014).","journal-title":"Blood"},{"key":"467_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","volume":"126","author":"SM Jaglowski","year":"2015","unstructured":"Jaglowski, S. M. et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study. Blood 126, 842\u2013850 (2015).","journal-title":"Blood"},{"key":"467_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3324\/haematol.2014.107011","volume":"100","author":"F Da Roit","year":"2015","unstructured":"Da Roit, F. et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 100, 77\u201386 (2015).","journal-title":"Haematologica"},{"key":"467_CR28","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","volume":"100","author":"M Borge","year":"2015","unstructured":"Borge, M. et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica 100, e140\u2013e142 (2015).","journal-title":"Haematologica"},{"key":"467_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.blre.2017.05.002","volume":"31","author":"LA Butler","year":"2017","unstructured":"Butler, L. A., Tam, C. S. & Seymour, J. F. Dancing partners at the ball: rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. Blood reviews 31, 318\u2013327 (2017).","journal-title":"Blood reviews"},{"key":"467_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","volume":"22","author":"M Skarzynski","year":"2016","unstructured":"Skarzynski, M. et al. Interactions between ibrutinib and Anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin. Cancer Res. 22, 86\u201395 (2016).","journal-title":"Clin. Cancer Res."},{"key":"467_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","volume":"15","author":"JA Burger","year":"2014","unstructured":"Burger, J. A. et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 15, 1090\u20131099 (2014).","journal-title":"Lancet Oncol."},{"key":"467_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger, J. A. et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133, 1011\u20131019 (2019).","journal-title":"Blood"},{"key":"467_CR33","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach, J. A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. 379, 2517\u20132528 (2018).","journal-title":"N. Engl. J. Med."},{"key":"467_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt, T. D. et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N. Engl. J. Med. 381, 432\u2013443 (2019).","journal-title":"N. Engl. J. Med."},{"key":"467_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno, C. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 43\u201356 (2019).","journal-title":"Lancet Oncol."},{"key":"467_CR36","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2352-3026(19)30113-9","volume":"6","author":"AS Michallet","year":"2019","unstructured":"Michallet, A. S. et al. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 6, e470\u2013e479 (2019).","journal-title":"Lancet Haematol."},{"key":"467_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjh.14447","volume":"176","author":"JP Sharman","year":"2017","unstructured":"Sharman, J. P. et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br. J. Haematol. 176, 412\u2013420 (2017).","journal-title":"Br. J. Haematol."},{"key":"467_CR38","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.1200\/JCO.2017.35.15_suppl.7504","volume":"35","author":"JP Sharman","year":"2017","unstructured":"Sharman, J. P. et al. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study. J. Clin. Oncol. 35, 7504\u20137504 (2017).","journal-title":"J. Clin. Oncol."},{"key":"467_CR39","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst, B. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17, 928\u2013942 (2016).","journal-title":"Lancet Oncol."},{"key":"467_CR40","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","volume":"29","author":"K Fischer","year":"2011","unstructured":"Fischer, K. et al. Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 29, 3559\u20133566 (2011).","journal-title":"J. Clin. Oncol."},{"key":"467_CR41","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek, M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164\u20131174 (2010).","journal-title":"Lancet"},{"key":"467_CR42","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak, T. et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1756\u20131765 (2010).","journal-title":"J. Clin. Oncol."},{"key":"467_CR43","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17474086.2017.1350166","volume":"10","author":"MJ Gordon","year":"2017","unstructured":"Gordon, M. J., Lewis, L. D., Brown, J. R. & Danilov, A. V. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities\u2014is there an optimal dose? Expert Rev. Hematol. 10, 707\u2013718 (2017).","journal-title":"Expert Rev. Hematol."},{"key":"467_CR44","first-page":"57","volume":"89","author":"EA Stadnik","year":"2017","unstructured":"Stadnik, E. A. et al. Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: results of the BEN-001 study. Ter. Arkh. 89, 57\u201364 (2017).","journal-title":"Ter. Arkh."},{"key":"467_CR45","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3324\/haematol.2014.104661","volume":"99","author":"P Strati","year":"2014","unstructured":"Strati, P. et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99, 1350\u20131355 (2014).","journal-title":"Haematologica"},{"key":"467_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson, P. A. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127, 303\u2013309 (2016).","journal-title":"Blood"},{"key":"467_CR47","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","volume":"92","author":"MJ Keating","year":"1998","unstructured":"Keating, M. J. et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92, 1165\u20131171 (1998).","journal-title":"Blood"},{"key":"467_CR48","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","volume":"56","author":"O Benjamini","year":"2015","unstructured":"Benjamini, O. et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk. Lymphoma 56, 1643\u20131650 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"467_CR49","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41375-019-0597-3","volume":"34","author":"M F\u00fcrstenau","year":"2020","unstructured":"F\u00fcrstenau, M. et al. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia 34, 924\u2013928 (2020).","journal-title":"Leukemia"},{"key":"467_CR50","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","volume":"117","author":"D Bagnara","year":"2011","unstructured":"Bagnara, D. et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 117, 5463\u20135472 (2011).","journal-title":"Blood"},{"key":"467_CR51","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1182\/blood-2011-03-342709","volume":"117","author":"S Devereux","year":"2011","unstructured":"Devereux, S. Two-faced T cells in CLL. Blood 117, 5273\u20135274 (2011).","journal-title":"Blood"},{"key":"467_CR52","doi-asserted-by":"publisher","first-page":"99209","DOI":"10.18632\/oncotarget.22277","volume":"8","author":"A Vardi","year":"2017","unstructured":"Vardi, A., Stamatopoulos, K. & Hadzidimitriou, A. T cells in chronic lymphocytic leukemia: can they fight? Oncotarget 8, 99209\u201399210 (2017).","journal-title":"Oncotarget"},{"key":"467_CR53","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","volume":"125","author":"JR Brown","year":"2015","unstructured":"Brown, J. R. et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 125, 2915\u20132922 (2015).","journal-title":"Blood"},{"key":"467_CR54","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan, A. et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. The Lancet Oncology 17, 200\u2013211 (2016).","journal-title":"The Lancet Oncology"},{"key":"467_CR55","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","volume":"33","author":"G Fraser","year":"2019","unstructured":"Fraser, G. et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma. Leukemia 33, 969\u2013980 (2019).","journal-title":"Leukemia"},{"key":"467_CR56","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","volume":"6","author":"MS Davids","year":"2019","unstructured":"Davids, M. S. et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol 6, e419\u2013e428 (2019).","journal-title":"Lancet Haematol"},{"key":"467_CR57","first-page":"495","volume":"130","author":"N Jain","year":"2017","unstructured":"Jain, N. et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for first-line treatment of patients with CLL with mutated IGHV and without TP53 aberrations. Blood 130, 495\u2013495 (2017).","journal-title":"Blood"},{"key":"467_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","volume":"7","author":"R Lemal","year":"2019","unstructured":"Lemal, R. & Tournilhac, O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J. Immunother. Cancer 7, 202 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"467_CR59","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1038\/bcj.2015.86","volume":"5","author":"H Saito","year":"2015","unstructured":"Saito, H. et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 5, e362\u2013e362 (2015).","journal-title":"Blood Cancer J."},{"key":"467_CR60","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg, A. et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 15, 1567\u20131574 (1997).","journal-title":"J. Clin. Oncol."},{"key":"467_CR61","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long, M. et al. Ibrutinib treatment improves T cell number and function in CLL patients. J. Clin. Invest. 127, 3052\u20133064 (2017).","journal-title":"J. Clin. Invest."},{"key":"467_CR62","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122, 2539\u20132549 (2013).","journal-title":"Blood"},{"key":"467_CR63","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta, J. A. et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127, 1117\u20131127 (2016).","journal-title":"Blood"},{"key":"467_CR64","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/08820130600745430","volume":"35","author":"DT Fisher","year":"2006","unstructured":"Fisher, D. T. et al. Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol Invest. 35, 251\u2013277 (2006).","journal-title":"Immunol Invest."},{"key":"467_CR65","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","volume":"22","author":"M Ruella","year":"2016","unstructured":"Ruella, M. et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin. Cancer Res. 22, 2684\u20132696 (2016).","journal-title":"Clin. Cancer Res."},{"key":"467_CR66","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle, C. J. et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 35, 3010\u20133020 (2017).","journal-title":"J. Clin. Oncol."},{"key":"467_CR67","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier, J. et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 135, 1650\u20131660 (2020).","journal-title":"Blood"},{"key":"467_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-140622","volume":"136","author":"WG Wierda","year":"2020","unstructured":"Wierda, W. G. et al. Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Blood 136, 39\u201340 (2020).","journal-title":"Blood"},{"key":"467_CR69","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"467_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/cdd.2017.159","volume":"25","author":"Y Pekarsky","year":"2018","unstructured":"Pekarsky, Y., Balatti, V. & Croce, C. M. BCL2 and miR-15\/16: from gene discovery to treatment. Cell Death Differ. 25, 21\u201326 (2018).","journal-title":"Cell Death Differ."},{"key":"467_CR71","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","volume":"21","author":"F Cervantes-Gomez","year":"2015","unstructured":"Cervantes-Gomez, F. et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin. Cancer Res. 21, 3705\u20133715 (2015).","journal-title":"Clin. Cancer Res."},{"key":"467_CR72","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng, J. et al. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31, 2075\u20132084 (2017).","journal-title":"Leukemia"},{"key":"467_CR73","first-page":"3018","volume":"130","author":"E Slinger","year":"2017","unstructured":"Slinger, E., Balasubramanian, S., Leverson, J. D., Eldering, E. & Kater, A. P. Combinatorial treatment of chronic lymphocytic leukemia with ibrutinib and venetoclax is superior to treatment with single agents in the TCL1 mouse model. Blood 130, 3018\u20133018 (2017).","journal-title":"Blood"},{"key":"467_CR74","doi-asserted-by":"publisher","first-page":"e0171221","DOI":"10.1371\/journal.pone.0171221","volume":"12","author":"A Yahiaoui","year":"2017","unstructured":"Yahiaoui, A. et al. PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO\/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors. PLoS ONE 12, e0171221 (2017).","journal-title":"PLoS ONE"},{"key":"467_CR75","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","volume":"125","author":"MFM de Rooij","year":"2015","unstructured":"de Rooij, M. F. M. et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood 125, 2306\u20132309 (2015).","journal-title":"Blood"},{"key":"467_CR76","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain, N. et al. Ibrutinib and venetoclax for first-line treatment of CLL. N. Engl. J. Med. 380, 2095\u20132103 (2019).","journal-title":"N. Engl. J. Med."},{"key":"467_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2019-121424","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam, C. S. et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study. Blood 134, 35\u201335 (2019).","journal-title":"Blood"},{"key":"#cr-split#-467_CR78.1","doi-asserted-by":"crossref","unstructured":"Wierda, W. G. et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. In Presented at: the 2020 ASH Annual Meeting and Exposition","DOI":"10.1182\/blood-2020-134446"},{"key":"#cr-split#-467_CR78.2","unstructured":"December 5-8, 2020. Abstract #123 (2020)."},{"key":"467_CR79","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood-2019-131732","volume":"134","author":"N Jain","year":"2019","unstructured":"Jain, N. et al. Combined ibrutinib and venetoclax in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). Blood 134, 359\u2013359 (2019).","journal-title":"Blood"},{"key":"467_CR80","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen, P. et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY Study. J. Clin. Oncol. 37, 2722\u20132729 (2019).","journal-title":"J. Clin. Oncol."},{"key":"467_CR81","first-page":"428","volume":"130","author":"P Hillmen","year":"2017","unstructured":"Hillmen, P. et al. Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (bloodwise TAP CLARITY study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. Blood 130, 428\u2013428 (2017).","journal-title":"Blood"},{"key":"467_CR82","unstructured":"Munir, T., Boucher, R. H. & Webster, N. Continued long term responses to ibrutinib + venetoclax for relapsed\/refractory CLL in the Blood Cancer UK TAP Clarity trial. Presented at: the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; December 5\u20138, 2020. Abstract 124 (2020)."},{"key":"467_CR83","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2019-124377","volume":"134","author":"CU Niemann","year":"2019","unstructured":"Niemann, C. U. et al. Venetoclax and ibrutinib for patients with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL)\u201415-month safety, response and MRD evaluation: third interim analysis from the phase II vision HO141 trial. Blood 134, 4292\u20134292 (2019).","journal-title":"Blood"},{"key":"467_CR84","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1200\/JCO.20.00491","volume":"38","author":"KA Rogers","year":"2020","unstructured":"Rogers, K. A. et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-na\u00efve and relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 38, 3626\u20133637 (2020).","journal-title":"J. Clin. Oncol."},{"key":"467_CR85","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","volume":"6","author":"MS Davids","year":"2019","unstructured":"Davids, M. S. et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 6, e38\u2013e47 (2019).","journal-title":"Lancet Haematol."},{"key":"467_CR86","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","volume":"6","author":"LJ Nastoupil","year":"2019","unstructured":"Nastoupil, L. J. et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 6, e100\u2013e109 (2019).","journal-title":"Lancet Haematol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00467-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00467-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00467-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:44:08Z","timestamp":1669909448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00467-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00467-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.G. has received research grants from Pharmacyclics, Acerta, AbbVie, Gilead, Sunesis, Infinity, Loxo Oncology, and ClearCreek Bio. N.T. reports no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"79"}}